MSI

MEDICINES SECURITY INSTITUTE

STRATEGIC PAPER 02 - SEPTEMBER 2026

Artificial Intelligence and Medicines Security

Building decision advantage without creating new systemic risks.

Executive argument

AI can improve forecasting, dependency discovery, quality surveillance and scenario analysis. Its value depends on reliable data, accountable human judgement and safeguards against cyber, model and concentration risks.

High-value applications

Priority uses include demand sensing, shortage prediction, supplier-network mapping, anomaly detection and simulation of policy options. Applications should support defined decisions rather than become detached technology projects.

Governance requirements

Institutions need documented purposes, validated data, human escalation, performance monitoring and clear accountability. Critical decisions require assurance and workable alternatives when systems fail.

Conclusion

AI should augment medicines-security institutions, not substitute for them.

Institutional note

This foundational paper advances the Medicines Security Institute's developing research programme. It supports informed discussion and does not constitute medical, legal or investment advice.